methotrexate has been researched along with Atherogenesis in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.77) | 29.6817 |
| 2010's | 42 (80.77) | 24.3611 |
| 2020's | 7 (13.46) | 2.80 |
| Authors | Studies |
|---|---|
| Babalic, FCA; Banciu, CD; Borza, C; Caraba, AE; Chelu, SC; Gurban, CV; Ilie Rosca, C; Kundnani, NR; Marius, P; Mederle, OA; Popa, MD; Sharma, A | 1 |
| Schattner, A | 1 |
| Tschöpe, C; Van Linthout, S | 1 |
| Anderson, DR; Clemens, DL; Duryee, MJ; Hall, JH; Klassen, LW; Mikuls, TR; Thiele, GM; Zimmerman, MC | 1 |
| Bassu, S; Carru, C; Erre, GL; Mangoni, AA; Piga, M; Sotgia, S; Tommasi, S; Zinellu, A | 1 |
| Ataman, S; Kucuksahin, O; Ozdemirel, AE; Sepici Dincel, A; Sunar, I; Tecer, D; Tural, R | 1 |
| Du, W; Han, B; Hou, J; Hou, S; Huang, X; Liu, D; Liu, Q; Lv, H; Nie, H; Sun, Y; Wang, G; Wang, X; Yang, M; Yu, B; Zhang, L; Zhang, R | 1 |
| Ridker, PM | 3 |
| Hernandez, AV; Roman, YM; White, CM | 1 |
| Catelani, T; Cervadoro, A; Decuzzi, P; Di Francesco, V; Ferreira, MFMM; Gurgone, D; Maffia, P; Palomba, R | 1 |
| Chen, J; Cooper, D; Norling, LV | 1 |
| Amano, K; Hatta, K; Kanazawa, T; Kume, K; Kuwaba, N; Ohta, H; Yamada, S | 1 |
| Chistiakov, DA; Grechko, AV; Melnichenko, AA; Myasoedova, VA; Orekhov, AN | 1 |
| Carru, C; Erre, GL; Mangoni, AA; Piga, M; Sotgia, S; Zinellu, A | 1 |
| Carvalho, PO; Gomes, FLT; Hatab, SA; Higuchi, ML; Kalil-Filho, R; Maranhão, RC; Mattos, FR; Pitta, FG; Serrano, CV; Tavares, ER | 1 |
| Bell, T; Currier, JS; Daar, ES; Deeks, SG; Fichtenbaum, C; Havlir, D; Hsue, PY; Lederman, M; Ribaudo, HJ; Ridker, PM; Stein, JH; Tawakol, A; Yeh, E | 1 |
| Bertrand, O; Butman, S; Clearfield, M; Everett, BM; Glynn, RJ; Goldhaber, SZ; Gupta, M; Hasan, A; Iturriaga, E; Johnston, J; Le May, M; Libby, P; MacFadyen, JG; Mam, V; Ofori, C; Paynter, NP; Pradhan, A; Ridker, PM; Rosenberg, Y; Saklayen, M; Seagle, R; Singh, N; Solomon, DH; Tsigoulis, M; Verma, S; Zaharris, E | 1 |
| Le Bras, A | 1 |
| Currier, JS; Hsue, PY; Korcarz, C; Mitchell, CKC; Ribaudo, H; Ridker, PM; Stein, JH; Tawakol, A; Weber, JM; Yeh, E | 1 |
| Nurmohamed, M; van Vollenhoven, RF | 1 |
| Goyal, M; Pandey, A | 1 |
| Carsons, SE; De Leon, J; Kasselman, LJ; Khalfan, M; Reiss, AB; Silverman, A; Vernice, NA | 1 |
| Clearfield, M; Everett, BM; Glynn, RJ; Gupta, M; Hasan, AA; Libby, P; Macfadyen, J; Paynter, N; Pradhan, AD; Ridker, PM; Solomon, DH; Zaharris, E | 1 |
| Bulgarelli, A; Dias, AA; Leite, AC; Maranhão, RC | 1 |
| Castro Cabezas, M; Hazes, JM; Klop, B; van Breukelen-van der Stoep, DF; van Zeben, D | 1 |
| Arora, J; Blair, IA; Hammons, AL; Jochems, J; Summers, CM; Whitehead, AS; Zhang, S | 1 |
| De Vusser, P; Dens, J; Geusens, P; Puttevils, D | 1 |
| Lüscher, TF; Ridker, PM | 1 |
| Adorni, MP; Bernini, F; Borghi, MO; Favalli, EG; Favari, E; Gatti, R; Greco, D; Hjeltnes, G; Hollan, I; Meroni, PL; Mikkelsen, K; Ronda, N; Zimetti, F | 1 |
| Bäck, M; Hansson, GK | 1 |
| Leite, AC; Maranhão, RC; Solano, TV; Tavares, ER | 1 |
| Nakamura, K; Shinozuka, K; Yoshikawa, N | 1 |
| Philipsen, P; Skiveren, J; Therming, G | 1 |
| Bachta, A; Bogusławska-Walecka, R; Duda, K; Juszkiewicz, A; Kisiel, B; Kruszewski, R; Kłos, K; Płoski, R; Raczkiewicz, A; Staniszewska-Varga, J; Tłustochowicz, M; Tłustochowicz, W | 1 |
| Glišić, B; Lepić, T; Petronijević, M; Ristić, AD; Ristić, GG; Stanisavljević, D; Stefanović, DZ; Subota, V | 1 |
| Atikan, BY; Mir, S; Ozdemir, K; Sozeri, B | 1 |
| Chen, S; Hou, J; Liu, Q; Wang, Y; Xing, J; Yu, B; Zhang, H; Zhang, R; Zhao, Q | 1 |
| Bohr, AH; Müller, KG; Nielsen, CH; Pedersen, FK | 1 |
| Arida, A; Fragiadaki, K; Kitas, GD; Konstantonis, G; Protogerou, AD; Sfikakis, PP | 1 |
| Anwar, K; Carsons, SE; Chan, ES; Cronstein, BN; Edelman, SD; Fernandez, P; Rao, S; Reiss, AB; Zhang, H | 1 |
| Blair, IA; Huang, Y; Jensen, LE; Kealey, C; Lu, ZY; Whitehead, AS | 1 |
| Bruckert, E; Hansel, B | 1 |
| Al-Husain, A; Bruce, IN; Mirjafari, H | 1 |
| Bulgarelli, A; Caramelli, B; Maranhão, RC; Martins Dias, AA | 1 |
| Ajeganova, S; de Faire, U; Frostegård, J; Hafström, I; Jogestrand, T | 1 |
| Acin, F; Bleda, S; De Haro, J; Esparza, L | 1 |
| Chui, RK; Kuan, WP; Kun, EW; Lee, KL; Leung, MH; Leung, YY; Li, EK; Li, M; Li, RJ; Li, TK; Shang, Q; Tam, LS; Tseung, L; Wong, S; Yim, CW; Ying, KY; Yu, CM; Yu, SL; Zhu, TY | 1 |
| Chui, RK; Kuan, WP; Kun, EW; Lee, KL; Leung, MH; Leung, YY; Li, EK; Li, M; Li, RJ; Li, TK; Shang, Q; Tam, LS; Tseung, L; Wang, S; Yim, CW; Ying, KY; Yu, CM; Yu, SL; Zhu, TY | 1 |
| Aslanidis, S; Doumas, M; Gavriilaki, E; Gkaliagkousi, E; Petidis, K; Stella, D | 1 |
| Fishman, EK; Kiani, AN; Petri, M | 1 |
18 review(s) available for methotrexate and Atherogenesis
| Article | Year |
|---|---|
The Cardiovascular Burden of Rheumatoid Arthritis - Implications for Treatment.
Topics: Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Methotrexate; Risk Factors | 2023 |
The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atherosclerosis; Calgranulin A; Calgranulin B; Cytokines; Drug Development; Heart Failure; Humans; Immunologic Factors; Inflammation; Mesenchymal Stem Cell Transplantation; Methotrexate; NLR Family, Pyrin Domain-Containing 3 Protein; T-Lymphocytes, Regulatory; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2019 |
Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease.
Topics: Animals; Antioxidants; Atherosclerosis; Cardiovascular Diseases; Doxycycline; Humans; Inflammation; Lipid Peroxidation; Malondialdehyde; Methotrexate; Oxidative Stress; Reactive Oxygen Species | 2020 |
Methotrexate and Vasculoprotection: Mechanistic Insights and Potential Therapeutic Applications in Old Age.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Endothelium, Vascular; Humans; Meta-Analysis as Topic; Methotrexate; Observational Studies as Topic; Systematic Reviews as Topic | 2019 |
The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Colchicine; Female; Humans; Immunity, Innate; Inflammation; Male; Methotrexate; Middle Aged; Treatment Outcome | 2020 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Etanercept; Heart Failure; Humans; Hydroxychloroquine; Inflammation; Methotrexate; Myocardial Infarction; Myocardial Ischemia; Risk Factors; Stroke Volume; Sulfasalazine | 2021 |
Potential of anti-inflammatory agents for treatment of atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Colchicine; Cyclooxygenase 2 Inhibitors; Cytokines; Humans; Inflammation; Leukotrienes; Methotrexate; Molecular Targeted Therapy; Phospholipase A2 Inhibitors; Signal Transduction | 2018 |
Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence.
Topics: Adenosine; AMP-Activated Protein Kinases; Atherosclerosis; Cytokines; Endothelium, Vascular; Humans; Interleukin-1; Interleukin-6; Methotrexate; Tumor Necrosis Factor-alpha | 2017 |
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; CD40 Antigens; CD40 Ligand; Diabetes Mellitus, Type 2; Disease Models, Animal; Hematopoiesis; Humans; Inflammasomes; Interleukin-18; Interleukin-1beta; Interleukin-6; Methotrexate; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Signal Transduction; Stroke; Thrombosis; Triggering Receptor Expressed on Myeloid Cells-1 | 2019 |
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Humans; Methotrexate; Tumor Necrosis Factor-alpha | 2019 |
Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Methotrexate; Risk Factors; Risk Reduction Behavior; Tumor Necrosis Factor-alpha | 2013 |
Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Belgium; Cardiovascular Diseases; Drug Therapy, Combination; Endothelium, Vascular; Evidence-Based Medicine; Humans; Methotrexate; Risk Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Anti-inflammatory therapies for cardiovascular disease.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; C-Reactive Protein; Carrier Proteins; Cell Adhesion Molecules; Colchicine; Humans; Hydroxychloroquine; Interleukin-1; Interleukin-6; Leukotriene Antagonists; Lipoproteins, HDL; Methotrexate; NLR Family, Pyrin Domain-Containing 3 Protein; Phospholipase A2 Inhibitors; Receptors, Interleukin-1; Serpins; Signal Transduction; Sirtuins; Thrombosis; Tumor Necrosis Factor-alpha; Vaccination | 2014 |
Anti-inflammatory therapies for atherosclerosis.
Topics: Allopurinol; Anti-Inflammatory Agents; Atherosclerosis; Biological Products; Colchicine; Humans; Methotrexate; Phospholipases; Signal Transduction; Tumor Necrosis Factor-alpha; Vaccination | 2015 |
Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis.
Topics: Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Antineoplastic Agents; Atherosclerosis; Cell Line, Tumor; Cordyceps; Deoxyadenosines; Drug Therapy, Combination; Humans; Kupffer Cells; Medicine, Chinese Traditional; Methotrexate; Models, Biological; Neoplasm Metastasis; Pentostatin; Phytotherapy; Plant Extracts; Receptor, Adenosine A3; Signal Transduction | 2015 |
[Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Chronic Disease; Dyslipidemias; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Lipid Metabolism; Lipids; Lipoproteins; Male; Methotrexate; Risk Factors | 2010 |
Cardiovascular risk factors in inflammatory arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hydroxychloroquine; Methotrexate; Risk Factors | 2011 |
Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Autoimmune Diseases; Cardiovascular Diseases; Carotid Arteries; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Methotrexate; Pulse Wave Analysis; Regional Blood Flow; Risk Factors; Stem Cells; Tunica Intima; Tunica Media; Vascular Calcification; Vascular Stiffness; Vasodilation | 2012 |
6 trial(s) available for methotrexate and Atherogenesis
| Article | Year |
|---|---|
Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
Topics: Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Atherosclerosis; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Methotrexate; Middle Aged | 2019 |
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Confidence Intervals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-1beta; Interleukin-6; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Statistics, Nonparametric; Stroke; Transaminases | 2019 |
Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate.
Topics: Adult; Atherosclerosis; Biomarkers; Brachial Artery; CD4 Lymphocyte Count; Double-Blind Method; Female; Fibrin Fibrinogen Degradation Products; HIV Infections; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler; United States | 2018 |
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Topics: Algorithms; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Inflammation; Metabolic Syndrome; Methotrexate; Myocardial Infarction; Research Design | 2013 |
Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Blood Flow Velocity; Carotid Intima-Media Thickness; Drug Substitution; Drug Therapy, Combination; Female; Health Status; Humans; Infliximab; Joints; Male; Methotrexate; Middle Aged; Pulse Wave Analysis; Severity of Illness Index; Treatment Failure; Vascular Stiffness | 2012 |
Aortic valve calcification in systemic lupus erythematosus.
Topics: Adult; Aortic Valve Stenosis; Atherosclerosis; Calcinosis; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Prednisone; Prevalence; Risk Factors; Tomography, Spiral Computed | 2006 |
28 other study(ies) available for methotrexate and Atherogenesis
| Article | Year |
|---|---|
Endothelial dysfunction in psoriatic arthritis patients: correlations between insulin resistance and disease activity.
Topics: Arthritis, Psoriatic; Atherosclerosis; Brachial Artery; Case-Control Studies; Endothelium, Vascular; Humans; Inflammation; Insulin Resistance; Methotrexate; Tumor Necrosis Factor-alpha | 2022 |
Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Case-Control Studies; Female; Homeostasis; Humans; Insulin Resistance; Leflunomide; Lipoproteins, HDL; Lipoproteins, LDL; Male; Methotrexate; Middle Aged; Risk; Statistics, Nonparametric; Triglycerides; Tumor Necrosis Factor Inhibitors | 2019 |
Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.
Topics: Adaptor Proteins, Signal Transducing; Adenylate Kinase; Animals; Apoptosis; Atherosclerosis; Atorvastatin; Cell Nucleus; Gene Silencing; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; Male; Methotrexate; Mice, Inbred C57BL; Models, Biological; Phosphorylation; Plaque, Atherosclerotic; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2019 |
From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Colchicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Lipid Metabolism; Methotrexate; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction | 2020 |
Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; Diet, High-Fat; Interleukin-1beta; Lipoproteins, LDL; Liposomes; Macrophages; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Knockout; Nanomedicine; Nanoparticles; Particle Size; Phosphatidylethanolamines; RAW 264.7 Cells | 2020 |
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol; Cohort Studies; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Single-Blind Method; Surveys and Questionnaires; Ultrasonography; Up-Regulation | 2017 |
Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cardiovascular Agents; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Inflammation Mediators; Lipids; Liposomes; Male; Matrix Metalloproteinase 9; Methotrexate; Nanoparticles; Paclitaxel; Plaque, Atherosclerotic; Rabbits | 2018 |
Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Atherosclerosis; Humans; Interleukin-1beta; Methotrexate; Randomized Controlled Trials as Topic | 2019 |
No benefit of methotrexate on the risk of cardiovascular events.
Topics: Antirheumatic Agents; Atherosclerosis; Humans; Immunosuppressive Agents; Methotrexate | 2019 |
Methotrexate for Prevention of Cardiovascular Events.
Topics: Antirheumatic Agents; Atherosclerosis; Humans; Methotrexate | 2019 |
Methotrexate: CIRTified for preventing atherosclerotic events?
Topics: Antirheumatic Agents; Atherosclerosis; Hospitalization; Humans; Methotrexate; Myocardial Infarction; Stroke | 2019 |
Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Cells, Cultured; Cholesterol, Dietary; Cytokines; Emulsions; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 9; Methotrexate; Nanoparticles; Rabbits; Receptors, LDL | 2013 |
Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells.
Topics: Antimetabolites, Antineoplastic; Atherosclerosis; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cell Survival; Folic Acid; Folic Acid Antagonists; Folic Acid Deficiency; Gene Expression; Humans; Inflammation; Methotrexate; Phenotype | 2014 |
Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Cholesterol; Female; Humans; In Vitro Techniques; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Male; Methotrexate; Middle Aged; Scavenger Receptors, Class B | 2015 |
Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits.
Topics: Animals; Aorta; Atherosclerosis; Drug Therapy, Combination; Emulsions; Etoposide; Lipids; Male; Methotrexate; Nanostructures; Rabbits | 2015 |
Patients with psoriasis have insufficient knowledge of their risk of atherothrombotic disease and metabolic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Psoriatic; Atherosclerosis; Depressive Disorder; Diabetes Mellitus; Female; Health Knowledge, Attitudes, Practice; Humans; Hypertension; Immunosuppressive Agents; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Obesity; Patient Education as Topic; Psoriasis; Risk Factors; Thrombosis; Young Adult | 2015 |
Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Products; Carotid Intima-Media Thickness; Case-Control Studies; Cyclosporine; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prevalence; Severity of Illness Index | 2015 |
Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Early Diagnosis; Female; Humans; Methotrexate; Middle Aged; Risk Factors; von Willebrand Factor | 2015 |
Assessment of vascular function in systemic onset juvenile idiopathic arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis, Juvenile; Atherosclerosis; Child; Child, Preschool; Cross-Sectional Studies; Endothelium, Vascular; Female; Humans; Male; Methotrexate; Pulse Wave Analysis; Risk Factors; Turkey; Vascular Stiffness | 2016 |
Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study.
Topics: Animals; Atherosclerosis; Carotid Artery Diseases; Cytokines; Disease Models, Animal; Drug-Eluting Stents; Image Processing, Computer-Assisted; Immunohistochemistry; Inflammation; Male; Methotrexate; NF-kappa B; Rabbits; Reproducibility of Results; Stents; Tomography, Optical Coherence | 2016 |
Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Atherosclerosis; Biomarkers; Blood Sedimentation; Body Mass Index; C-Reactive Protein; Child; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Exercise; Female; Humans; Leukocyte L1 Antigen Complex; Male; Methotrexate; Overweight; Treatment Outcome; Waist-Hip Ratio; Young Adult | 2016 |
Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Factors; Carotid Artery Diseases; Carotid Intima-Media Thickness; Case-Control Studies; Disease Progression; Female; Femoral Artery; Humans; Male; Methotrexate; Middle Aged; Plaque, Atherosclerotic; Prednisolone; Vascular Stiffness | 2017 |
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages.
Topics: Adenosine; Antirheumatic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cells, Cultured; Cholestanetriol 26-Monooxygenase; Cholesterol; Cyclooxygenase 2 Inhibitors; Down-Regulation; Drug Interactions; Foam Cells; Humans; Interferon-gamma; Macrophages; Methotrexate; Monocytes; Receptor, Adenosine A2A; RNA, Messenger | 2008 |
The up-regulation of monocyte chemoattractant protein-1 (MCP-1) in Ea.hy 926 endothelial cells under long-term low folate stress is mediated by the p38 MAPK pathway.
Topics: Atherosclerosis; Cell Line; Chemokine CCL2; Cytokines; Disease Progression; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Humans; Inflammation; Methotrexate; Models, Biological; p38 Mitogen-Activated Protein Kinases; Transcription, Genetic; Up-Regulation | 2009 |
Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Atherosclerosis; Cell Movement; Cell Proliferation; Cholesterol, Dietary; Dose-Response Relationship, Drug; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Macrophages; Male; Methotrexate; Myocytes, Smooth Muscle; Rabbits; Tumor Necrosis Factor-alpha; Up-Regulation | 2012 |
Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
Topics: Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Comorbidity; Disability Evaluation; Disease Progression; Female; Health Status; Humans; Immunity, Innate; Incidence; Lipoproteins, LDL; Male; Methotrexate; Middle Aged; Phosphorylcholine; Prospective Studies; Severity of Illness Index; Survival Rate; Sweden; Ultrasonography | 2012 |
Non-Fas(CD95/APO1)-mediated apoptosis of activated T cells inhibits the development of atherosclerosis.
Topics: Animals; Aorta, Thoracic; Apoptosis; Atherosclerosis; Cholesterol; Disease Models, Animal; fas Receptor; Immunity, Cellular; Immunomodulation; Immunosuppressive Agents; Male; Methotrexate; Mice; Mice, Inbred C57BL; Prognosis | 2012 |
Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prospective Studies; Pulse Wave Analysis; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Treatment Outcome; Vascular Stiffness | 2013 |